Cargando…

Ubrogepant: First Approval

Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in...

Descripción completa

Detalles Bibliográficos
Autor principal: Scott, Lesley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062659/
https://www.ncbi.nlm.nih.gov/pubmed/32020557
http://dx.doi.org/10.1007/s40265-020-01264-5